The goals of the proposed research are to identify two types of regulatory T cells, NK T cells and CD4+CD25+ T cells, in the peripheral blood (PB) and/or other lymphoid tissues in mice and humans, and to determine the ability of the Treg cells to alter the alloreactivity of conventional, non-regulatory T cells (Tnon-reg cells) in the context of allogeneic bone marrow (BM) or """"""""mobilized"""""""" PB hematopoietic progenitor transplantation. In the proposed mouse studies, we will determine whether defined mixtures of C57BL/6 Treg and Tnon-reg cells allow for full chimerism and tumor cell eradication without graft versus host disease (GVHD) after injection into lethally irradiated BALB/c hosts. We will test the hypothesis that tumor eradication mediated by donor CD8+Tnon-reg cells via perforin and FasL pathways are not inhibited by Treg cells. We will also test the hypothesis that Treg cells inhibit GVHD by suppressing the expansion of donor Tnon-reg cells, and by suppressing changes in cell trafficking molecules on Tnon-reg cells that ordinarily allow them to migrate from the lymphoid tissues to sites of GVHD target tissue injury such as the gut and liver. Key trafficking molecules to be studied include CD62L, beta7integrin, CCR7, and CXCR3. We will determine whether deficiencies in these molecules prevent GVHD. Expression of these molecules will be measured by flow cytometry and real-time PCR analyses. Finally we will identify the levels of Treg cells in normal human PB mononuclear cells (PBMC), and assay their capacity to inhibit alloreactivity of Tnon-reg cells in vitro in the mixed leukocyte reaction (MLR) and cell mediated lympholysis (CML) assays.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL058250-09
Application #
7213430
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Di Fronzo, Nancy L
Project Start
1997-01-01
Project End
2009-03-31
Budget Start
2007-04-01
Budget End
2009-03-31
Support Year
9
Fiscal Year
2007
Total Cost
$342,944
Indirect Cost
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Yao, Zhenyu; Jones, Jennifer; Kohrt, Holbrook et al. (2011) Selective resistance of CD44hi T cells to p53-dependent cell death results in persistence of immunologic memory after total body irradiation. J Immunol 187:4100-8
Kohrt, Holbrook E; Müller, Antonia; Baker, Jeanette et al. (2011) Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation. Blood 118:5319-29
Dutt, Suparna; Baker, Jeanette; Kohrt, Holbrook E et al. (2011) CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD. Blood 117:3230-9
Yao, Zhenyu; Liu, Yinping; Jones, Jennifer et al. (2009) Differences in Bcl-2 expression by T-cell subsets alter their balance after in vivo irradiation to favor CD4+Bcl-2hi NKT cells. Eur J Immunol 39:763-75
Pillai, Asha B; George, Tracy I; Dutt, Suparna et al. (2009) Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood 113:4458-67
Liu, Yin Ping; Li, Zengqi; Nador, Roland G et al. (2008) Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: role of natural killer T cells. Transplantation 85:607-14
Dutt, Suparna; Tseng, Diane; Ermann, Joerg et al. (2007) Naive and memory T cells induce different types of graft-versus-host disease. J Immunol 179:6547-54
Pillai, A; Teo, P; George, T et al. (2007) Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation. Bone Marrow Transplant 40:487-97
Pillai, Asha B; George, Tracy I; Dutt, Suparna et al. (2007) Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol 178:6242-51
Takahashi, Tsuyoshi; Dejbakhsh-Jones, Sussan; Strober, Samuel (2006) Expression of CD161 (NKR-P1A) defines subsets of human CD4 and CD8 T cells with different functional activities. J Immunol 176:211-6

Showing the most recent 10 out of 23 publications